Response to: "consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients with Colorectal Liver Metastases"

Geoffrey Yuet Mun Wong, Rajiv Kumar, Carol Beeke, Shahid Ullah, John Chen, Christos S. Karapetis, Timothy J. Price, Rob Padbury

Research output: Contribution to journalLetter

Abstract

We would like to thank Dr. Margonis and colleagues for their response to our article and considerate comments. Our study had demonstrated that indeterminate extrahepatic disease in the lungs, as identified by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography had a predictive value in identifying patients at risk for site-specific recurrence.1 In their response, Margonis and colleagues had proposed the integration of Kirsten Rat Sarcoma (KRAS) mutation status to improve the prognostic impact of indeterminate colorectal lung metastases in patients being considered for resection of colorectal liver metastasis.
Original languageEnglish
Pages (from-to)e9-e10
Number of pages2
JournalAnnals of Surgery
Volume268
Issue number1
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint Dive into the research topics of 'Response to: "consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients with Colorectal Liver Metastases"'. Together they form a unique fingerprint.

  • Cite this